- Trials with a EudraCT protocol (53)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
53 result(s) found for: COVID-19.
Displaying page 1 of 3.
EudraCT Number: 2021-001103-32 | Sponsor Protocol Number: HEPCOViVac | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: The HEPCOViVac Registry - Immunological response in patients with liver disease vaccinated against COVID-19 | ||
Medical condition: Cirrhotic chronic liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001459-15 | Sponsor Protocol Number: HS-2021-02 | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study | ||
Medical condition: Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-004166-37 | Sponsor Protocol Number: 100424 | Start Date*: 2023-05-02 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric oxygenation for patients with orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID. Prospectively randomized cross- over study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001327-13 | Sponsor Protocol Number: OnCoVID19Trial | Start Date*: 2020-04-21 |
Sponsor Name:Med. Univ. Wien | ||
Full Title: A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVI... | ||
Medical condition: Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005094-28 | Sponsor Protocol Number: VAC3_COVID-19_antibody_study_V1 | Start Date*: 2021-10-21 |
Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology | ||
Full Title: Population-based prospective, clinical study on efficacy and safety of a booster COVID-19 vaccination | ||
Medical condition: SARS-CoV-2 infection prevention | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001040-10 | Sponsor Protocol Number: CoVVac | Start Date*: 2021-04-26 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study | |||||||||||||
Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003277-55 | Sponsor Protocol Number: CAR-CF | Start Date*: 2021-09-01 | ||||||||||||||||
Sponsor Name:Medical University of Innsbruck, University Clinic for Pediatrics III | ||||||||||||||||||
Full Title: COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF | ||||||||||||||||||
Medical condition: COVID-19 vaccine Antibody response from natural infection or after vaccination in patients with Cystic Fibrosis (CF) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006172-16 | Sponsor Protocol Number: CoVVacBoost | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study | |||||||||||||
Medical condition: Covid (Coronavirus disease)- 19 immunisation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001391-42 | Sponsor Protocol Number: Speed-Covid | Start Date*: 2021-05-12 |
Sponsor Name:Medical University of Graz | ||
Full Title: Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study | ||
Medical condition: For assessing the immune cell function after COVID-19 vaccine, peripheral blood mononuclear cells (PBMC) will be separated after blood sampling and measurements as follows will be done: • FACS anal... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001126-21 | Sponsor Protocol Number: 100423 | Start Date*: 2021-04-14 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric Oxygenation for patients with post-COVID-19 sequelae. Pilot study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002984-23 | Sponsor Protocol Number: 33-391ex20/21 | Start Date*: 2021-08-01 |
Sponsor Name:Medical University of Graz | ||
Full Title: Retrospective quantification of anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in patients treated with peritoneal dialysis | ||
Medical condition: Chronic peritoneal dialysis patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005580-32 | Sponsor Protocol Number: Sili | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Pilot study on silibinin as a possible therapeutic agent for mildly ill COVID-19 patients | ||
Medical condition: antiviral effect of silibinin against SARS-CoV2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002693-10 | Sponsor Protocol Number: VAC3_SARS-CoV2_seroconversion_study | Start Date*: 2021-07-15 |
Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology | ||
Full Title: A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination in Immunocompromised Patients with Inadequate Humoral Response after Primary mRNA SARS-CoV-2 (Covid-19) Vaccination | ||
Medical condition: Vaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficiencies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000291-11 | Sponsor Protocol Number: IMRES | Start Date*: 2021-05-30 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19) | |||||||||||||
Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002171-19 | Sponsor Protocol Number: HEVACC | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck, Institut für Virologie | |||||||||||||
Full Title: Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost | |||||||||||||
Medical condition: Immunization for SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006877-44 | Sponsor Protocol Number: 7081-031 | Start Date*: 2024-01-24 |
Sponsor Name:Fachhochschule Salzburg GmbH | ||
Full Title: Factors influencing SARS-CoV-2 antibody formation | ||
Medical condition: Prevention or lindering of the symtoms in the course of a covid-19 disease due to vaccination with SARS-CoV-2 directed vaccins. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001682-12 | Sponsor Protocol Number: MYOFLAME-19 | Start Date*: 2023-06-16 | ||||||||||||||||
Sponsor Name:Goethe University Frankfurt | ||||||||||||||||||
Full Title: Randomised placebo controlled clinical trial of efficacy of MYOcardial protection with postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19) | ||||||||||||||||||
Medical condition: Inflammatory cardiovascular involvement due to COVID-19, defined by Cardiovascular magnetic resonance imaging | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002030-16 | Sponsor Protocol Number: Shieldvacc2 | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck, Institut für Virologie | |||||||||||||
Full Title: Immune response and breakthrough infections following an in-label vaccination with Comirnaty against SARS-CoV-2 in the district of Schwaz | |||||||||||||
Medical condition: SARS-CoV-2 infections | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001329-30 | Sponsor Protocol Number: 2020P000787 | Start Date*: 2020-04-09 |
Sponsor Name:Massachussetts General Hospital | ||
Full Title: Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 | ||
Medical condition: ARDS caused by COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
